类风湿关节炎、银屑病关节炎和强直性脊柱炎中二线生物制剂治疗的优化
意大利ITABIO委员会系统综述文献,评估RA、SpA和PsA患者二线生物制剂选择的最佳策略。结果显示,在抗TNF失败后,RA中戈利木单抗证据最高,PsA和AS中换用第二种抗TNF advisable;非抗TNF药物中利妥昔单抗和托珠单抗证据最强。
要点
- RA患者抗TNF失败后,戈利木单抗作为二线生物制剂证据等级最高。
- PsA和AS患者第一种抗TNF失败后,建议换用第二种抗TNF。
- 非抗TNF靶向药物中,利妥昔单抗和托珠单抗对抗TNF失败证据最强。
核心结论
- 鉴于对照试验缺乏,RA、SpA和PsA患者的二线生物制剂治疗可合理优化。
研究设计与样本
- 系统综述英文文献,数据来自随机对照试验、国家生物制剂登记、国家医疗数据库、上市后调查和开放标签观察性研究。
主要发现
- 患者偏好、潜在育龄女性抗TNF单药治疗指征以及肥胖受试者静脉途径剂量滴定这三个变量在三种风湿病中均有效。
- RA中,戈利木单抗作为二线生物制剂在抗TNF失败中证据等级最高。
- 出现不良事件的应答患者优先换药策略,严重或类别特异性副作用应选择不同靶点药物。
- 依那西普继发应答不足应使用非抗TNF生物制剂;两次或以上抗TNF失败后推荐换用不同作用机制。
- PsA和AS患者第一种抗TNF失败后建议换用第二种抗TNF,需考虑阿达木单抗在葡萄膜炎患者中的疗效证据。
关键数值与推荐
- RA中戈利木单抗作为二线生物制剂在抗TNF失败中证据等级最高。
- 非抗TNF靶向生物制剂中,利妥昔单抗和托珠单抗在抗TNF失败治疗中证据最强。
- PsA中银屑病严重程度、关节受累以及附着点炎和/或指趾炎为主可驱动选择乌司奴单抗或司库奇尤单抗,AS中后者适用。
临床怎么用
- RA患者抗TNF失败后可优先考虑戈利木单抗;非抗TNF药物中利妥昔单抗和托珠单抗证据较强。
- PsA和AS患者第一种抗TNF失败后,可换用第二种抗TNF;PsA根据银屑病和关节受累特征选择乌司奴单抗或司库奇尤单抗。
局限性
- 对照试验缺乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Italian board for the TAilored BIOlogic therapy (ITABIO) reviewed the most consistent literature to indicate the best strategy for the second-line biologic choice in patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA). METHODS: Systematic review of the literature to identify English-language articles on efficacy of second-line biologic choice in RA, PsA, and ankylosing spondylitis (AS). Data were extracted from available randomized, controlled trials, national biologic registries, national healthcare databases, post-marketing surveys, and open-label observational studies. RESULTS: Some previously stated variables, including the patients׳ preference, the indication for anti-tumor necrosis factor (TNF) monotherapy in potential childbearing women, and the intravenous route with dose titration in obese subjects resulted valid for all the three rheumatic conditions. In RA, golimumab as second-line biologic has the highest level of evidence in anti-TNF failure. The switching strategy is preferable for responder patients who experience an adverse event, whereas serious or class-specific side effects should be managed by the choice of a differently targeted drug. Secondary inadequate response to etanercept (ETN) should be treated with a biologic agent other than anti-TNF. After two or more anti-TNF failures, the swapping to a different mode of action is recommended. Among non-anti-TNF targeted biologics, to date rituximab (RTX) and tocilizumab (TCZ) have the strongest evidence of efficacy in the treatment of anti-TNF failures. In PsA and AS patients failing the first anti-TNF, the switch strategy to a second is advisable, taking in account the evidence of adalimumab efficacy in patients with uveitis. The severity of psoriasis, of articular involvement, and the predominance of enthesitis and/or dactylitis may drive the choice toward ustekinumab or secukinumab in PsA, and the latter in AS. CONCLUSION: Taking in account the paucity of controlled trials, second-line biologic therapy may be reasonably optimized in patients with RA, SpA, and PsA.
引用
- Cantini F, Niccoli L, Nannini C, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum. 2017. PMID: 28413099. doi:10.1016/j.semarthrit.2017.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。